• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺酸性磷酸酶和前列腺特异性抗原与前列腺腺癌肿瘤分级的关系:一项免疫组织化学研究。

The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.

作者信息

Ersev A, Ersev D, Turkeri L, Ilker Y, Simsek F, Kullu S, Akdas A

机构信息

Department of Pathology, Marmara University School of Medicine, Istanbul, Turkey.

出版信息

Prog Clin Biol Res. 1990;357:129-34.

PMID:1699237
Abstract

This study examines the relationship between the presence of prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) in tissue, the serum PAP and PSA levels and tumour grade in prostatic adenocarcinoma. Thirty-three tumours were studied by the indirect immunoperoxidase method for PAP and PSA production. Thirty-one of them were stained positive for both markers. The remaining two which previous histopathological studies suggested were transitional cell carcinoma, stained negative. In primary tumours there was a weak trend for poor immunoreactivity in high grade neoplasms but the correlation was not significant. The elevated serum PAP and PSA levels did not correlate with the intensity of staining in the tissue.

摘要

本研究探讨前列腺腺癌组织中前列腺酸性磷酸酶(PAP)和前列腺特异性抗原(PSA)的存在、血清PAP和PSA水平与肿瘤分级之间的关系。采用间接免疫过氧化物酶法对33个肿瘤进行PAP和PSA生成研究。其中31个肿瘤两种标志物染色均呈阳性。其余两个经先前组织病理学研究提示为移行细胞癌,染色呈阴性。在原发性肿瘤中,高级别肿瘤免疫反应性较差有微弱趋势,但相关性不显著。血清PAP和PSA水平升高与组织中的染色强度无关。

相似文献

1
The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.前列腺酸性磷酸酶和前列腺特异性抗原与前列腺腺癌肿瘤分级的关系:一项免疫组织化学研究。
Prog Clin Biol Res. 1990;357:129-34.
2
Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.高级别前列腺癌与尿路上皮癌的免疫组织化学鉴别
Am J Surg Pathol. 2007 Aug;31(8):1246-55. doi: 10.1097/PAS.0b013e31802f5d33.
3
[Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
Pathologica. 1989 Mar-Apr;81(1072):109-26.
4
Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
Clin Invest Med. 1997 Dec;20(6):371-80.
5
Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.前列腺标志物的临床应用。I. 利用免疫组织化学技术对前列腺肿瘤进行分类。
Scand J Urol Nephrol Suppl. 1988;107:65-70.
6
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.高级别前列腺腺癌和尿路上皮癌的免疫表型
Mod Pathol. 2000 Nov;13(11):1186-91. doi: 10.1038/modpathol.3880220.
7
[Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].[肿瘤标志物在前列腺癌中的临床意义——前列腺酸性磷酸酶、前列腺特异性抗原和γ-精浆蛋白的比较研究]
Hinyokika Kiyo. 1987 Dec;33(12):2044-9.
8
Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.转移性前列腺癌中前列腺特异性抗原前体形式(proPSA)的免疫组织化学染色
Am J Surg Pathol. 2006 Oct;30(10):1231-6. doi: 10.1097/01.pas.0000213332.94615.8a.
9
The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.P501S和前列腺特异性抗原(PSA)在前列腺转移性腺癌诊断中的作用。
Am J Surg Pathol. 2007 Sep;31(9):1351-5. doi: 10.1097/PAS.0b013e3180536678.
10
Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.高级别膀胱尿路上皮癌和前列腺腺癌的免疫组织化学特征
Hum Pathol. 2002 Nov;33(11):1136-40. doi: 10.1053/hupa.2002.129416.

引用本文的文献

1
Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.激素抵抗性前列腺腺癌。治疗前和治疗后标本中预后因素的评估。
Br J Cancer. 1993 Aug;68(2):380-4. doi: 10.1038/bjc.1993.344.